When VCs hand out mega-rounds to Vir and Gossamer, are they betting on the jockey or the horse?
Following a period of unprecedented returns for biopharma investors, flush VCs are sinking bigger and bigger rounds of cash into companies whose pipelines are still in their infancy. Taking this trend to a new level is an increasingly popular move to back biotech executives who are known to be star performers with mega-rounds rising north of $100 million – even if their pipelines lack a star program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.